Cyclosporine for plaque-type psoriasis: Results of a multidose, double-blind trial

New England Journal of Medicine

Volumn 324, Issue 5, 1991, Pages 277-284

  Ellis, Charles N ^a   Fradin, Mark S ^a   Brown, Marc D ^a   Siegel, Michael T ^a   Hartley, A Howland ^a   Wheeler, Suzanne ^a   Hamilton, Ted A ^a   Parish, Thomas G ^a   Ellis Madu, Mary ^a   Duell, Elizabeth ^a   Cooper, Kevin D ^a   Voorhees, John J ^a   Messana, Joseph M ^a   Rocher, Leslie L ^a   Annesley, Thomas M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETRETINATE; METHOTREXATE; PLACEBO; PSORALEN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS;

ADMINISTRATION, ORAL; ADULT; AGED; CYCLOSPORINS; DOUBLE-BLIND METHOD; FEMALE; HUMAN; HYPERSENSITIVITY, DELAYED; KIDNEY; MALE; MIDDLE AGE; PSORIASIS; SKIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026013163     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199101313240501     Document Type: Article

References (39)

1. Mueller W., Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979; 301:555.
2. Ellis C.N., Gorsulowsky D.C., Hamilton T.A., et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986; 256:3110-3116
3. Müller W., Graf U. Die behandlung der Psoriasis-Arthritis mit Cyclosporin A, einem neuen Immunosuppressivum. Schweiz Med Wochenschr 1981; 111:408-413
4. Harper J.I., Keat A.S.C., Staughton R.C.D. Cyclosporin for psoriasis. Lancet 1984; 2:981-982
5. van Hooff J.P., Leunissen K.M.L., Staak W.V.D. Cyclosporin and psoriasis. Lancet 1985; 1:335.
6. Marks J. Psoriasis. BMJ 1986; 293:509.
7. Griffiths C.E.M., Powles A.V., Leonard J.N., Fry L., Baker B.S., Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. BMJ 1986; 293:731-732
8. Brookes D.B. Clearance of psoriasis with low dose cyclosporin. BMJ 1986; 293:1098-1099
9. van Joost T., Heule F., Stolz E., Beukers R. Short-term use of cyclosporin A in severe psoriasis. Br J Dermatol 1986; 114:615-620
10. Wentzell J.M., Baughman R.D., O#x0027;Connor G.T., Bemier G.M. Jr. Cyclosporine in the treatment of psoriasis. Arch Dermatol 1987; 123:163-165
11. Picascia D.D., Garden J.M., Freinkel R.K., Roenigk H.H. Jr. Treatment of resistant severe psoriasis with systemic cyclosporine. J Am Acad Dermatol 1987; 17:408-414
12. Griffiths C.E.M., Powles A.V., Baker B.S., Fry L., Valdimarsson H. Combination of cyclosporine A and topical corticosteroid in the treatment of psoriasis. Transplant Proc 1988; 20:Suppl 4:50-52
13. van Joost T., Bos J.D., Heule F., Meinardi M.M.H.M. Low-dose cyclosporin A in severe psoriasis: a double-blind study. Br J Dermatol 1988; 118:183-190
14. Meinardi M.M.H.M., Bos J.D. Cyclosporine maintenance therapy in psoriasis. Transplant Proc 1988; 20:Suppl 4:42-49
15. Finzi A.F., Mozzanica N., Cattaneo A., Chiappino G., Pigatto P.D. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol 1989; 21:91-97
16. Heule F., Bousema M.T., Laeijendecker R., van Joost T. Three long-term regimens with cyclosporin for psoriasis vulgaris. Acta Derm Venereol Suppl (Stockh) 1989; 146:171-175
17. Meinardi M.M.H.M., de Rie M.A., Bos J.D. Oral cyclosporin A in the treatment of psoriasis: an overview of studies performed in The Netherlands. Br J Dermatol 1990; 122:Suppl 36:27-31.
18. Timonen P., Friend D., Abeywickrama K., Laburte C., von Graffenried B., Feutren G. Efficacy of low-dose cyclosporin A in psoriasis: results of dosefinding studies. Br J Dermatol 1990; 122:Suppl 36:33-39
19. Chapman D.G., Nam J. Asymptotic power of chi square tests for linear trends in proportions. Biometrics 1968; 24:315-327
20. Annesley T., Matz K., Balogh L., Clayton L., Giacherio D. Liquid-chromatographic analysis for cyclosporine with use of a microbore column and small sample volume. Clin Chem 1986; 32:1407-1409
21. Fradin M.S., Ellis C.N., Voorhees J.J. Management of patients and side effects during cyclosporine therapy for cutaneous disorders. J Am Acad Dermatol 1990; 23:1265-1275
22. Fredriksson T., Pettersson U. Severe psoriasis — oral therapy with a new retinoid. Determatologica 1978; 157:238-244
23. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
24. Kniker W.T., Anderson C.T., Roumiantzeff M. The multi-test system: a standardized approach to evaluation of delayed hypersensitivity and cell-mediated immunity. Ann Allergy 1979; 43:72-79
25. Bennett W.M. Discussion to Messana JM, Rocher LL, Ellis CN, et al. Effects of cyclosporine on renal function in psoriasis patients. J Am Acad Dermatol 1990; 23:1288-1293
26. Fisher G.J., Duell E.A., Nickoloff B.J., et al. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media. J Invest Dermatol 1988; 91:142-146
27. Feutren G., Friend D., Timonen P., Barnes A., Laburte C. Predictive value of cyclosporin A level for efficacy or renal dysfunction in psoriasis. Br J Dermatol 1990; 122:Suppl 36:85-93.
28. de Groen P.C., Aksamit A.J., Rakela J., Forbes G.S., Krom R.A.F. Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med 1987; 317:861-866
29. Xue H., Bukoski R.D., McCarron D.A., Bennett W.M. Induction of contraction in isolated rat aorta by cyclosporine. Transplantation 1987; 43:715-718
30. Curtis J.J., Luke R.G., Dubovsky E., Diethelm A.G., Whelchel J.D., Jones P. Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; 2:447-449
31. Powles A.V., Carmichael D., Hulme B., et al. Renal function after long-term low-dose cyclosporin for psoriasis. Br J Dermatol 1990; 122:665-669
32. Gilbert S.C., Emmett M., Menter A., Silverman A., Klintmalm G. Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function. J Am Acad Dermatol 1989; 21:470-474
33. Krueger G.G., Hill H.R., Jederberg W.W. Inflammatory and immune cell function in psoriasis — a subtle disorder. I. In vivo and in vitro survey. J Invest Dermatol 1978; 71:189-194
34. Obalek S., Haftek M., Slinski W. Immunological studies in psoriasis: the quantitative evaluation of cell-mediated immunity in patients with psoriasis by experimental sensitization to 2,4-dinitrochlorobenzene. Dermatologica 1977; 155:13-25.
35. McFadden J.P., Powles A.V., Baker B.S., Valdimarsson H., Fry L. Intradermal antigen tests in psoriasis. Acta Derm Venereol (Stockh) 1990; 70:262-264
36. Ho V.C., Griffiths C.E.M., Ellis C.N., et al. Intralesional cyclosporine A in the treatment of psoriasis: a clinical and pharmacokinetic study. J Am Acad Dermatol 1990; 20:94-100.
37. Black K.S., Nguyen D.K., Proctor C.M., Patel M.P., Hewitt C.W. Site-specific suppression of cell-mediated immunity by cyclosporine. J Invest Dermatol 1990; 94:644-648
38. Cooper K.D., Baadsgaard O., Ellis C.N., Duell E.A., Voorhees J.J. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis. J Invest Dermatol 1990; 94:649-656
39. Baker B.S., Powles A.V., Savage C.R., McFadden J.P., Valdimarsson H., Fry L. Intralesional cyclosporin in psoriasis: effects on T lymphocyte and dendritic cell subpopulations. Br J Dermatol 1989; 120:207-213